Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy

Back, 2002, Therapeutic drug monitoring in HIV infection: current status and future directions, AIDS, 16, S5, 10.1097/00002030-200203001-00002 Liu, 2010, Therapeutic drug monitoring in highly active antiretroviral therapy, Expert Opin Drug Saf, 9, 743, 10.1517/14740331003767395 Kredo, 2009, Therapeutic drug monitoring of antiretrovirals for people with HIV, Cochrane Database Syst Rev, 10.1002/14651858.CD007268.pub2 Lee, 2014, Sleep quality in efavirenz-treated Chinese HIV patients—comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms, Int J STD AIDS, 25, 193, 10.1177/0956462413498581 Gutiérrez, 2005, Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring, Clin Infect Dis, 41, 1648, 10.1086/497835 Dickinson, 2015, Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naïve HIV-infected patients: results of the ENCORE1 study, Clin Pharmacol Ther, 98, 406, 10.1002/cpt.156 Sinxadi, 2015, Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa, Br J Clin Pharmacol, 80, 146, 10.1111/bcp.12590 Holzinger, 2012, Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants, Pharmacogenet Genomics, 22, 858, 10.1097/FPC.0b013e32835a450b Stahle, 2004, Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects, Ther Drug Monit, 26, 267, 10.1097/00007691-200406000-00008 Lehmann, 2015, Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS Clinical Trials Group protocols, Pharmacogenet Genomics, 25, 51, 10.1097/FPC.0000000000000106 Marzolini, 2001, Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients, AIDS, 15, 71, 10.1097/00002030-200101050-00011 Leth, 2006, Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy, AIDS Res Hum Retroviruses, 22, 232, 10.1089/aid.2006.22.232 Orrell, 2011, Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy, AIDS Res Treat, 2011, 469127 Orrell, 2007, Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited, Antivir Ther, 12, 83, 10.1177/135965350701200106 Orrell, 2015, A randomised controlled trial of real-time electronic adherence monitoring with text message dosing reminders in people starting first-line antiretroviral therapy, J Acquir Immune Defic Syndr, 70, 495, 10.1097/QAI.0000000000000770 Dooley, 2015, Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection, J Infect Dis, 211, 197, 10.1093/infdis/jiu429 McIlleron, 2013, Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype, AIDS, 27, 1933, 10.1097/QAD.0b013e328360dbb4 R Development Core Team, 2015 Therneau Therneau, 2000 Andersen, 1982, Cox's regression model for counting processes: a large sample study, Ann Stat, 10, 1100, 10.1214/aos/1176345976 Klein, 2003 Bienczak, 2015 Cohen, 2009, Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa, Antivir Ther, 14, 687, 10.1177/135965350901400502 Haas, 2004, Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study, AIDS, 18, 2391